Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin

Fidaxomicin versus Vancomycin forClostridium difficileInfection

(2011) Thomas J. Louie et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fidaxomicin: A Macrocyclic Antibiotic for the Management of Clostridium difficile Infection

(2010) Karyn M Sullivan et al.   ANNALS OF PHARMACOTHERAPY

Fidaxomicin (OPT-80) for the treatment ofClostridium difficileinfection

(2010) Mark Miller   EXPERT OPINION ON PHARMACOTHERAPY

Clostridium difficileinfection: update on emerging antibiotic treatment options and antibiotic resistance

(2010) Dhara Shah et al.   Expert Review of Anti-Infective Therapy

Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment ofClostridium difficileinfections

(2010) Ian R Poxton   Future Microbiology

Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)

(2010) Stuart H. Cohen et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Treatment of Refractory/Recurrent C. difficile-associated Disease by Donated Stool Transplanted Via Colonoscopy

(2010) Sonia S. Yoon et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin

(2010) G. W. Tannock et al.   MICROBIOLOGY-SGM

High Frequency of Rifampin Resistance Identified in an EpidemicClostridium difficileClone from a Large Teaching Hospital

(2009) Scott R. Curry et al.   CLINICAL INFECTIOUS DISEASES

European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI)

(2009) M.P. Bauer et al.   CLINICAL MICROBIOLOGY AND INFECTION

Clostridium difficile: controversies and approaches to management

(2009) Martijn P Bauer et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Recurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes

(2009) Stuart Johnson   JOURNAL OF INFECTION

Rifampin and Rifaximin Resistance in Clinical Isolates of Clostridium difficile

(2008) J. R. O'Connor et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C. difficile Infection

(2008) T. J. Louie et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Both Oral Metronidazole and Oral Vancomycin Promote Persistent Overgrowth of Vancomycin-Resistant Enterococci during Treatment of Clostridium difficile-Associated Disease

(2008) W. N. Al-Nassir et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model

(2008) S. D. Baines et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Decreased Diversity of the Fecal Microbiome in RecurrentClostridium difficile–Associated Diarrhea

(2008) Ju Young Chang et al.   JOURNAL OF INFECTIOUS DISEASES